The research program will fund technology development and implementation grants that use new stem cell technologies to understand genetic variation and disease.
A program supported by NIGMS and NICHD will give grants to studies that will use molecular or genomic approaches evaluating behavior in animal models.
The strategic partnerships will use multi-disciplinary research to study how multi-analyte signatures of tumors may be applied to cancer treatments.
Funded with $1.25 million in 2010, the grants will support studies of epigenetic factors that affect disease symptoms and complications.
NCI and NHLBI plan to give $12 million each for research into molecular, genetic, and other connections between the two diseases.
The CADET programs will support two-year projects for centers to develop diagnostics and therapeutics for lung diseases.
With up to $25 million, the MAPGen organ system centers will study underlying causes of heart, lung, blood, and sleep disorders.
The non-profit institute will use $6.7 million to establish an NCI Integrative Cancer Biology Program Center.
The Centralized Protein Sequence and Function Resource would house proteomics and related information for researchers.
The $20 million program will support development of tools for NIAID priorities including diagnostics, therapeutics, vaccines, and others.
Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.
The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.
One gene regulates hundreds of others to influence facial development, according to New Scientist.
In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.